Table 3.

Inhibitors of mitochondrial translation

Drug	Disease	Clinical trial	Participants	Doses	Outcome
COL-3	Advanced solid tumors	NCT00003721	33	N/A	Completed, no results reported.
	Brain tumors	NCT00004147	33	25 mg/m2/day	The study was designed to evaluate the maximum tolerate dose of COL-3 in patients with recurrent high-grade glioma in combination with enzyme-inducing anti-seizure drugs. It showed that administration of COL-3 alone only had a partial response and didn't warrant further studies as a standalone therapy [127].
	Kaposi's sarcoma	N/A	18	25, 50 or 70 mg/m2/day	Patients with AIDS-related Kaposi's sarcoma were assessed for changes in blood levels of metalloproteinases (MMP)-2, -9 and vascular endothelial growth factor (VEGF). The treatment was well tolerated and induced both a decline in MMP-2 serum levels and tumour regression [128].
		NCT00020683	75	50 or 100 mg	Patients with AIDS-related Kaposi's sarcoma were given one of two doses of COL-3. The lower daily dosage of COL-3 was shown to have a greater response rate compared to the higher dose group. In both dose groups a significant decrease in MMP-2 and MMP-9 serum levels was observed, along with antitumour activity [129].
	Soft tissue sarcomas	N/A	15	50 mg/m2/day	Patients with soft tissue sarcomas were treated with COL-3 to assess the effects of the drug on disease progression and survival. Treatment did not yield an attenuation of disease progression [130].
Tigecycline	AML	NCT01332786	27	50 to 350 mg/day	Completed, no results reported.
	CML	NCT02883036	100 (estimated)	N/A	Not yet recruiting.